MAP3K13 and neoplasm: Based on the greater than 90% homology in the kinase domains of LZK and DLK, here we tested the use of a DLK inhibitor as an inhibitor of LZK and this effective LZK inhibitor was then assessed for the ability to reduce HNSCC cell viability and suppress tumor growth in vivo.